ストックスクリーナーアプリを入手
376.41
1.57%
-6.00
アフターアワーズ：
376.41
前日終値:
$382.41
開ける：
$383.05
24時間の取引高:
324.35K
Relative Volume:
1.12
時価総額：
$10.06B
収益：
$2.59B
当期純損益:
$168.80M
株価収益率:
61.96
EPS:
6.0748
ネットキャッシュフロー:
$357.20M
1週間 パフォーマンス:
+1.92%
1か月 パフォーマンス:
+6.73%
6か月 パフォーマンス:
+40.46%
1年 パフォーマンス:
+31.39%
1日の値動き範囲:
$374.81
$383.05
1週間の範囲:
$365.66
$385.71
52週間の値動き範囲:
$236.73
$396.23
Bio Rad Laboratories Inc Stock (BIO) Company Profile
名前
Bio Rad Laboratories Inc
セクター
電話
(510) 724-7000
住所
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
376.41 | 9.87B | 2.59B | 168.80M | 357.20M | 6.0748 |
ABT
Abbott Laboratories
|
102.61 | 176.41B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.13 | 116.35B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.12 | 105.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.34 | 62.29B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
88.26 | 48.63B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-07 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-10-01 | アップグレード | Citigroup | Neutral → Buy |
| 2024-08-28 | 開始されました | Wells Fargo | Equal Weight |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2024-04-03 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-12-07 | 開始されました | UBS | Buy |
| 2023-06-16 | 開始されました | Wells Fargo | Overweight |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-01-28 | 繰り返されました | Citigroup | Buy |
| 2020-01-08 | 開始されました | Wells Fargo | Overweight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2018-10-17 | 開始されました | Goldman | Buy |
| 2018-09-20 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-02-16 | ダウングレード | CL King | Buy → Neutral |
| 2017-07-13 | 開始されました | Wells Fargo | Outperform |
| 2017-06-28 | アップグレード | Deutsche Bank | Hold → Buy |
| 2017-01-18 | 開始されました | Deutsche Bank | Hold |
| 2016-10-13 | 開始されました | CL King | Buy |
| 2015-05-06 | 繰り返されました | Jefferies | Buy |
| 2009-12-18 | 開始されました | Maxim Group | Buy |
| 2009-11-06 | 開始されました | Jefferies & Co | Buy |
| 2009-07-17 | 開始されました | Soleil | Buy |
| 2007-09-26 | 開始されました | Banc of America Sec | Buy |
| 2007-02-23 | ダウングレード | Robert W. Baird | Outperform → Neutral |
すべてを表示
Bio Rad Laboratories Inc (BIO) 最新ニュース
Bio-Rad Laboratories, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
BIO-RAD LABORATORIES (NYSE: BIO) Grants 719 Derivative Securities to Director Allison Schwartz - Kalkine Media
BIO-RAD LABORATORIES Executive Evran Sedat Reports Exercising 3,880 Shares (NYSE: BIO) - Kalkine Media
Bio-Rad: Favorable Read-Across From Investor Event (NYSE:BIO) - Seeking Alpha
Bio-Rad (NYSE: BIO) director sees 320 RSUs convert, 116 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) EVP logs 4,313 RSU grant and 2,179 vested shares - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
1,453 stock units vest for Bio-Rad (NYSE: BIO) insider as 551 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com Canada
Bio-Rad Terminates Forbes Tate Lobbying Pact - Legis1
Bio-Rad expands range of Foresight prepacked chromatography columns for biomanufacturing - selectscience.net
Chromatography Reagents Market 2026-2030 | Global key Player; - openPR.com
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating Current Market Challenges with Strategic Insights - DirectorsTalk Interviews
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
BIO-RAD (NYSE: BIO) Director Allison Schwartz Reports 1,573 Shares Following Option Exercise - Kalkine Media
Mesa Laboratories Inc. (MLAB) Peer Comparison – Compare with Others - Value Research
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
RSU vesting gives Bio-Rad (NYSE: BIO) exec 425 shares - Stock Titan
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue? - finance.yahoo.com
Bio-Rad expands Foresight Pro prepacked chromatography columns with Nuvia ion exchange and mixed-mode resins - Manufacturing Chemist
Allied Healthcare Products Inc. (AHPI) Peer Comparison – Compare with Others - Value Research
Best Practices for qPCR Assay Design and Optimization - the-scientist.com
Bio-Rad expands Foresight Pro Prepacked Chromatography Columns with Nuvia Ion Exchange and Mixed-Mode Resins for Biomanufacturing - Cambridge Network
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare Conference - Investing News Network
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a Challenging Market with a -15.14% Potential Downside - DirectorsTalk Interviews
Discipline and Rules-Based Execution in BIO Response - Stock Traders Daily
Bio-Rad Laboratories Inc. Class A (BIO) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Bio-Rad Laboratories stock hits 52-week high at 394.22 USD - Investing.com Nigeria
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating the Upside Amidst Market Challenges - DirectorsTalk Interviews
Why Bio-Rad Laboratories (BIO) Is Up 6.7% After Restructuring Move Amid Mixed Segment Trends - Sahm
Return on invested capital % of Bio-Rad Laboratories, Inc. Class A – HAM:BUWA - TradingView
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation? - Yahoo Finance
Bio-Rad (BIO) Quarter in Focus: Profit Per Share Clears Its Benchmark for the Current Session - vinanet.vn
Bio-Rad Laboratories Inc (BIO) Shares Surge 3.4% -- What GF Scor - GuruFocus
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building? - Yahoo Finance
Westport Asset Management Inc. Invests $881,000 in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories stock hits 52-week high at $365.68 By Investing.com - Investing.com Nigeria
Bio-Rad Laboratories (NYSE:BIO) Reaches New 12-Month HighShould You Buy? - MarketBeat
Bio-Rad Laboratories stock hits 52-week high at $365.68 - Investing.com
Bio Rad Laboratories Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
S&P 500 Futures Decline In Premarket Trading; Bio-Rad Labs A, Fabrinet Lag - Moomoo
Sickle Cell Anemia Testing & Screening Industry Trends & Growth - SNS Insider
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Navigating a Challenging Market with Innovative Diagnostics - DirectorsTalk Interviews
Could Danaher Corporation (DHR)’s Bioprocessing Recovery Give Bio-Rad Laboratories (BIO) Stock a Boost? - Yahoo Finance
Bio-Rad Laboratories (NYSE:BIO) Upgraded to Hold at Zacks Research - MarketBeat
Bio-Rad Laboratories, Inc. (NYSE:BIO) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
First Trust Advisors LP Has $424,000 Position in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock forecasts - Yahoo Finance UK
Bio Rad Laboratories Inc (BIO) 財務データ
収益
当期純利益
現金流量
EPS
1.18%
1.44%
大文字化:
|
ボリューム (24 時間):